AstraZeneca Urges Chancery To Toss $3B Viela Bio Sale Suit
An attorney for AstraZeneca told a Delaware vice chancellor Tuesday that clinical stage biopharmaceutical company Viela Bio Inc. failed to show that AstraZeneca had the shares or clout needed to push...To view the full article, register now.
Already a subscriber? Click here to view full article